Multiple drugs have been associated with PRCA. 4 Recovering from anemia after drug discontinuation varies depending on the pharmacokinetics of the drug, metabolism, duration of treatment and mechanisms by which erythropoiesis is suppressed. The mechanism underlying anemia induction by an anti-IL17 biologic remains unclear. Although the predominant function of IL-17 is being a pro-inflammatory mediator, it could also be able to enhance production of hematopoietic growth factors which promote the growth and maturation of myeloid cells, favoring erythropoiesis. 5 Therefore, its inhibition could explain the development of anemia. To our knowledge, this is the first report of anemia in a psoriatic patient on ixekizumab, which resolved on discontinuation of the drug. Further studies and experience are needed to explore anemia as a potential adverse event in anti-IL17 biologic agents.